The U.S. Food and Drug Administration (FDA) has approved fremanezumab (Ajovy) to prevent migraines, the second drug targeting calcitonin gene-related peptide (CGRP) to gain FDA-approval and the first that will be available in quarterly, as well as monthly, dosing options. The first migraine drug in this class, erenumab (Aimovig), was approved in May 2018. Both are injectable medications.
These drugs block CGRP molecules from binding to receptor cells, preventing migraine attacks. Ajovy, which is made by Teva Pharmaceuticals, was evaluated in two clinical trials: one involving people with episodic migraine and one involving people with chronic migraine. Over 12 weeks, both groups experienced fewer monthly migraine days with fremanezumab.
In a 1-year follow-up study, people with chronic migraines continued to have fewer headaches each month, but 10 to 12 percent reported upper respiratory infections. Injection-site reactions were the most common side effect. A clinical trial investigating fremanezumab as a potential treatment for episodic cluster headache is underway.
Sourced from: Business Wire